TGF beta 1/TGFB1 Protein, Human (278a.a, HEK293, His)

The Latency-associated peptide (LAP) of Transforming growth factor beta-1 (TGF-beta-1) proprotein is a crucial precursor, forming a complex with TGF-beta-1. LAP maintains the latent state of TGF-beta-1 during extracellular matrix storage, ensuring controlled activation. Interactions with 'milieu molecules' like LTBP1, LRRC32/GARP, and LRRC33/NRROS intricately regulate TGF-beta-1 activation. LRRC33/NRROS influences activation in macrophages and microglia, while LRRC32/GARP controls activation on activated regulatory T-cells. Interactions with integrins induce conformational changes in LAP, releasing active TGF-beta-1. LAP orchestrates controlled TGF-beta-1 activation in diverse physiological contexts. TGF beta 1/TGFB1 Protein, Human (278a.a, HEK293, His) is the recombinant human-derived TGF beta 1/TGFB1 protein, expressed by HEK293 , with C-10*His labeled tag and C33S mutation. The total length of TGF beta 1/TGFB1 Protein, Human (278a.a, HEK293, His) is 249 a.a., with molecular weight of ~41.1 kDa.

The Latency-associated peptide (LAP) of Transforming growth factor beta-1 (TGF-beta-1) proprotein serves as a crucial precursor, forming a complex with TGF-beta-1 to constitute the regulatory and active subunits, respectively. LAP plays a pivotal role in maintaining the latent state of TGF-beta-1 during extracellular matrix storage, ensuring controlled activation upon specific triggers. Interactions with key 'milieu molecules' such as LTBP1, LRRC32/GARP, and LRRC33/NRROS intricately regulate TGF-beta-1 activation. LRRC33/NRROS influences TGF-beta-1 activation in macrophages and microglia, while LRRC32/GARP controls activation on activated regulatory T-cells (Tregs). Furthermore, interactions with integrins (ITGAV:ITGB6 or ITGAV:ITGB8) induce conformational changes in LAP, leading to the release of active TGF-beta-1. This dynamic interplay highlights LAP's crucial role in orchestrating the controlled activation of TGF-beta-1 in various physiological contexts.

Measured by its ability to inhibit proliferation of HT-2 mouse T cells. The ED₅₀ this effect is 0.02115 ng/ml, corresponding to a specific activity is 4.728×10^7 units/mg.

• 
  Measured by its ability to inhibit proliferation of HT-2 mouse T cells. The ED₅₀ for this effect is 0.02115 ng/mL, corresponding to a specific activity is 4.728×10⁷ units/mg.

Human

HEK293

C-10*His

P01137 (L30-R278, C33S)

7040  [NCBI]

LSTSKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRR

Approximately 41.1 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.